On consolidated basis
Quarter ended June 2026 compared with Quarter ended June 2025.
Net sales (including other operating income) of Alkem Laboratories has increased 10.95% to Rs 3740.15 crore. Operating profit margin has declined from 21.92% to 20.48%, leading to 3.65% rise in operating profit to Rs 766.05 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 24.15% to 23.85%. Purchase of finished goods cost fell from 11.60% to 9.59%. Employee cost increased from 20.25% to 21.20%. Other expenses rose from 22.42% to 25.27%. Other income rose 11.91% to Rs 152.75 crore. PBIDT rose 4.94% to Rs 918.8 crore. Provision for interest rose 56.55% to Rs 46.62 crore. PBDT rose 3.12% to Rs 872.18 crore. Provision for depreciation rose 14.27% to Rs 100.19 crore. Profit before tax grew 1.83% to Rs 771.99 crore. Share of profit/loss was 24.39% lower at Rs -0.51 crore. Provision for tax was expense of Rs 250.5 crore, compared to Rs 102.69 crore. Effective tax rate was 32.47% compared to 13.33%. Minority interest decreased 71.78% to Rs 1.03 crore. Net profit attributable to owners of the company decreased 21.72% to Rs 519.95 crore. Promoters’ stake was 49.70% as of 30 June 2026 ,compared to 53.04% as of 30 June 2025 .
Full year results analysis.
Net sales (including other operating income) of Alkem Laboratories has increased 13.48% to Rs 14712.27 crore. Operating profit margin has jumped from 19.38% to 20.43%, leading to 19.63% rise in operating profit to Rs 3,005.21 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 26.15% to 23.96%. Purchase of finished goods cost fell from 11.51% to 11.39%. Employee cost increased from 18.65% to 19.07%. Other expenses rose from 24.59% to 25.39%. Other income rose 18.15% to Rs 583.35 crore. PBIDT rose 19.38% to Rs 3588.56 crore. Provision for interest rose 32.11% to Rs 160.78 crore. Loan funds rose to Rs 2,047.16 crore as of 31 March 2026 from Rs 1,380.90 crore as of 31 March 2025. Inventories rose to Rs 3,333.22 crore as of 31 March 2026 from Rs 2,922.41 crore as of 31 March 2025. Sundry debtors were higher at Rs 2,979.11 crore as of 31 March 2026 compared to Rs 2,466.25 crore as of 31 March 2025. Cash and bank balance rose to Rs 1,732.90 crore as of 31 March 2026 from Rs 1,563.08 crore as of 31 March 2025. Investments rose to Rs 1,868.81 crore as of 31 March 2026 from Rs 1,845.50 crore as of 31 March 2025 . PBDT rose 18.85% to Rs 3427.78 crore. Provision for depreciation rose 6.97% to Rs 382.06 crore. Fixed assets increased to Rs 3,228.54 crore as of 31 March 2026 from Rs 2,977.27 crore as of 31 March 2025. Intangible assets increased from Rs 423.11 crore to Rs 924.28 crore. Profit before tax grew 20.53% to Rs 3,045.72 crore. Share of profit/loss was 217.74% lower at Rs -1.97 crore. Provision for tax was expense of Rs 517.76 crore, compared to Rs 311.03 crore. Effective tax rate was 18.05% compared to 12.31%. Minority interest decreased 1.08% to Rs 49.36 crore. Net profit attributable to owners of the company increased 6.30% to Rs 2,301.80 crore. Equity capital stood at Rs 23.91 crore as of 31 March 2026 to Rs 23.91 crore as of 31 March 2025. Per share face Value remained same at Rs 2.00. Promoters’ stake was 51.20% as of 31 March 2026 ,compared to 55.13% as of 31 March 2025 . Cash flow from operating activities increased to Rs 1,963.03 crore for year ended March 2026 from Rs 1,912.84 crore for year ended March 2025. Cash flow used in acquiring fixed assets during the year ended March 2026 stood at Rs 617.26 crore, compared to Rs 675.62 crore during the year ended March 2025. Other Highlights
In
Q1 FY27, the contribution of domestic sales to total
sales was 67.1%, and international business 32.9%.
In Q1 FY27, Acute segment reported growth
of 12.3% YoY vs IPM which grew by 10.1% YoY. Chronic segment reported growth of
17.9% YoY compared to IPM which grew by 15.4% YoY.
In Q1 FY27, US sales grew 6.5% YoY, and Non-US
sales grew 34.5% YoY.
As of June 30, 2026, the Company has filed
192 ANDAs, 2 NDAs and 1 BLA and has received 170 ANDAs approvals (including
18tentative approvals) and 2 NDAs approvals.
In terms of key therapy segment
performance, the anti-diabetic segment grew by 21.1% YoY in Q1 FY27,
anti-infectives grew by 7.9%, derma grew 16.5%, gastrointestinal grew by 12.2%,
neuro/CNS by 8.7%, pain/analgesics grew 20.2%, respiratory grew 16.8%, and VMN
grew 21.4%.
R&D
expenses for Q1 FY27 was Rs 150.2 crore representing 4% of total revenue from
operations.
Management Comments :
Mr. Sandeep Singh, MD of Alkem, said, “We
have started FY27 on a steady note, with healthy growth across our India and
international businesses. Our India business continued to outperform the
market, while the strong growth in our non-US international markets was
encouraging. At the same time, there are areas where we need to improve,
particularly in strengthening execution, addressing operational and regulatory
priorities, and improving the consistency of performance across our businesses.
We are also investing in R&D, MedTech and Biotech as we build our next
phase of growth. Our focus will be to strengthen the core, address the areas
that need improvement and build these newer opportunities in a disciplined
manner.”
| Alkem Laboratories : Consolidated Results | | | Quarter ended | Year ended |
|---|
| Particulars | 202606 | 202506 | Var.(%) | 202603 | 202503 | Var.(%) |
|---|
| Net Sales (including other operating income) | 3,740.15 | 3,371.14 | 10.95 | 14,712.27 | 12,964.52 | 13.48 | | OPM (%) | 20.48 | 21.92 | -144 bps | 20.43 | 19.38 | 105 bps | | OP | 766.05 | 739.05 | 3.65 | 3,005.21 | 2,512.15 | 19.63 | | Other Inc. | 152.75 | 136.49 | 11.91 | 583.35 | 493.74 | 18.15 | | PBIDT | 918.80 | 875.54 | 4.94 | 3,588.56 | 3,005.89 | 19.38 | | Interest | 46.62 | 29.78 | 56.55 | 160.78 | 121.70 | 32.11 | | PBDT | 872.18 | 845.76 | 3.12 | 3,427.78 | 2,884.19 | 18.85 | | Depreciation | 100.19 | 87.68 | 14.27 | 382.06 | 357.16 | 6.97 | | PBT | 771.99 | 758.08 | 1.83 | 3045.72 | 2527.03 | 20.53 | | Share of Profit/(Loss) from Associates | -0.51 | -0.41 | -24.39 | -1.97 | -0.62 | -217.74 | | PBT before EO | 771.48 | 757.67 | 1.82 | 3043.75 | 2526.41 | 20.48 | | EO Income | 0 | 12.93 | - | -174.83 | 0 | - | | PBT after EO | 771.48 | 770.6 | 0.11 | 2868.92 | 2526.41 | 13.56 | | Taxation | 250.5 | 102.69 | 143.94 | 517.76 | 311.03 | 66.47 | | PAT | 520.98 | 667.91 | -22.00 | 2351.16 | 2215.38 | 6.13 | | Minority Interest (MI) | 1.03 | 3.65 | -71.78 | 49.36 | 49.9 | -1.08 | | Net profit | 519.95 | 664.26 | -21.72 | 2301.8 | 2165.48 | 6.30 | | P/(L) from discontinued operations net of tax | 0 | 0 | - | 0 | 0 | - | | Net profit after discontinued operations | 519.95 | 664.26 | -21.72 | 2301.8 | 2165.48 | 6.30 | | EPS (Rs)* | 43.49 | 54.62 | -20.39 | 204.25 | 181.11 | 12.77 | | | * EPS is on current equity of Rs 23.91 crore, Face value of Rs 2, Excluding extraordinary items. | | # EPS is not annualised | | bps : Basis points | | EO : Extraordinary items | | Figures in Rs crore | | Source: Capitaline Corporate Database |
|
|